

Zahava Vadasz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8569505/publications.pdf>

Version: 2024-02-01

65
papers

1,708
citations

304743

22
h-index

302126

39
g-index

66
all docs

66
docs citations

66
times ranked

2071
citing authors

#	ARTICLE	IF	CITATIONS
1	The international EAACI/GA ² LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 734-766.	5.7	392
2	The possible involvement of sema3A and sema4A in the pathogenesis of multiple sclerosis. <i>Clinical Immunology</i> , 2022, 238, 109017.	3.2	3
3	The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 816-830.	5.7	58
4	Expression of Semaphorin 3A in Malignant and Normal Bladder Tissue: Immunohistochemistry Staining and Morphometric Evaluation. <i>Biology</i> , 2021, 10, 109.	2.8	0
5	Predictive features associated with chronic spontaneous urticaria recurrence. <i>Journal of Dermatology</i> , 2021, 48, 1786-1788.	1.2	3
6	Semaphorin3A is a promising therapeutic tool for bronchial asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 481-483.	5.7	6
7	Placenta-Derived Cell Therapy to Treat Patients With Respiratory Failure Due to Coronavirus Disease 2019. , 2020, 2, e0207.		13
8	Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 59, 38-45.	6.5	60
9	Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. <i>Clinical and Experimental Allergy</i> , 2020, 50, 799-804.	2.9	44
10	Articular angioedema in patients with chronic spontaneous urticaria is frequently misdiagnosed as arthritis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3232-3233.e1.	3.8	1
11	The Emerging Role of IL-17 in the Immune-Pathogenesis of Chronic Spontaneous Urticaria. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 217-223.	5.8	16
12	Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases. <i>Autoimmunity Reviews</i> , 2019, 18, 102369.	5.8	86
13	B Regulatory Cells in Autoimmunity. , 2019, , 21-28.		0
14	Semaphorin 3A Is Effective in Reducing Both Inflammation and Angiogenesis in a Mouse Model of Bronchial Asthma. <i>Frontiers in Immunology</i> , 2019, 10, 550.	4.8	24
15	Think autoimmunity, breath autoimmunity, and learn autoimmunity. <i>Clinical Rheumatology</i> , 2019, 38, 1227-1230.	2.2	1
16	Lysyl oxidase- a possible role in systemic sclerosis-associated pulmonary hypertension: a multicentre study. <i>Rheumatology</i> , 2019, 58, 1547-1555.	1.9	15
17	Innate immune-responses and their role in driving autoimmunity. <i>Autoimmunity Reviews</i> , 2019, 18, 306-311.	5.8	65
18	The Second Greek-Israeli Symposium on Autoimmunity and Rheumatology: Success Through Synergy. <i>Israel Medical Association Journal</i> , 2019, 21, 292-297.	0.1	0

#	ARTICLE	IF	CITATIONS
19	Increased killer B cells in chronic HCV infection may lead to autoimmunity and increased viral load. <i>Clinical and Experimental Immunology</i> , 2018, 193, 183-193.	2.6	4
20	Overexpression of semaphorin 3A in patients with urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 161.e1-161.e6.	1.6	9
21	Semaphorin 4D levels in heart failure patients: a potential novel biomarker of acute heart failure?. <i>ESC Heart Failure</i> , 2018, 5, 603-609.	3.1	18
22	Low levels of the immunoregulator Semaphorin 4D (CD100) in sera of HIV patients. <i>Clinical Immunology</i> , 2018, 191, 88-93.	3.2	7
23	Altered expression of regulatory molecules in the skin of psoriasis. <i>Immunologic Research</i> , 2018, 66, 649-654.	2.9	9
24	Semaphorin-3A inhibits multiple myeloma progression in a mouse model. <i>Carcinogenesis</i> , 2018, 39, 1283-1291.	2.8	16
25	Semaphorin3A: A Potential Therapeutic Tool for Lupus Nephritis. <i>Frontiers in Immunology</i> , 2018, 9, 634.	4.8	13
26	Semaphorin3A: A potential therapeutic tool in immune-mediated diseases. <i>European Journal of Rheumatology</i> , 2018, 5, 58-61.	0.6	17
27	Updates in Rheumatology and Autoimmunity in the Israel Medical Association Journal (IMAJ) 2018. <i>Israel Medical Association Journal</i> , 2018, 20, 645-648.	0.1	0
28	FoxP3 Expression in Macrophages, Cancer, and B Cells—Is It Real?. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 364-372.	6.5	29
29	Semaphorin 3A: Is a key player in the pathogenesis of asthma. <i>Clinical Immunology</i> , 2017, 184, 70-72.	3.2	26
30	The association between semaphorin 3A levels and gluten-free diet in patients with celiac disease. <i>Clinical Immunology</i> , 2017, 184, 73-76.	3.2	3
31	Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1743-1745.	3.8	42
32	Semaphorins 4A and 4D in chronic inflammatory diseases. <i>Inflammation Research</i> , 2017, 66, 111-117.	4.0	34
33	Rheumatology and Autoimmunity in The Israel Medical Association Journal (IMAJ): 2017. <i>Israel Medical Association Journal</i> , 2017, 19, 781-783.	0.1	0
34	Seasonal Exacerbation of Asthma Is Frequently Associated with Recurrent Episodes of Acute Urticaria. <i>International Archives of Allergy and Immunology</i> , 2016, 169, 263-266.	2.1	10
35	Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis. <i>Clinical Immunology</i> , 2016, 164, 114-118.	3.2	22
36	Semaphorin 3A, a potential immune regulator in familial Mediterranean fever. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S52-S55.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Adaptation and Validation of the Israeli Version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). Israel Medical Association Journal, 2016, 18, 461-465.	0.1	5
38	Lysyl Oxidase in Systemic Sclerosis: Getting Under the Skin. Israel Medical Association Journal, 2016, 18, 534-536.	0.1	2
39	The Involvement of Immune Semaphorins in the Pathogenesis of Inflammatory Bowel Diseases (IBDs). PLoS ONE, 2015, 10, e0125860.	2.5	18
40	The Expansion of CD25 ^{high} IL-10 ^{high} FoxP3 ^{high} B Regulatory Cells Is in Association with SLE Disease Activity. Journal of Immunology Research, 2015, 2015, 1-6.	2.2	34
41	Acute and Chronic Infections. , 2015, , 859-876.		0
42	A1.3â€¦Increased CD5 ^{high} Fas ^{high} B regulatory cells in patients with active HCV infection: association with disease severity and autoimmunity. Annals of the Rheumatic Diseases, 2015, 74, A1.3-A1.	0.9	0
43	Semaphorin 3A: an immunoregulator in systemic sclerosis. Rheumatology International, 2015, 35, 1625-1630.	3.0	28
44	A6.14â€¦Semaphorin 3A, an immunoregulator and potential biomarker for disease severity in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, A61.1-A61.	0.9	3
45	The role of increased T helper cell 2 cytokine expression in skin weals of chronic spontaneous urticaria: are they always activating cytokines?. British Journal of Dermatology, 2015, 172, 1185-1186.	1.5	2
46	The Role of B Regulatory Cells and Semaphorin3A in Atopic Diseases. International Archives of Allergy and Immunology, 2014, 163, 245-251.	2.1	17
47	Brief Report: Lysyl Oxidase Is a Potential Biomarker of Fibrosis in Systemic Sclerosis. Arthritis and Rheumatology, 2014, 66, 726-730.	5.6	62
48	Semaphorins: Their Dual Role in Regulating Immune-Mediated Diseases. Clinical Reviews in Allergy and Immunology, 2014, 47, 17-25.	6.5	63
49	A regulatory role for CD72 expression on B cells in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2014, 43, 767-771.	3.4	32
50	Cogan syndrome â€” Pathogenesis, clinical variants and treatment approaches. Autoimmunity Reviews, 2014, 13, 351-354.	5.8	69
51	A8.39â€¦Regulatory role for CD72 Expression on B cells in SLE. Annals of the Rheumatic Diseases, 2014, 73, A92.1-A92.	0.9	0
52	New potential biomarkers for disease activity and fibrosis in systemic sclerosis. Israel Medical Association Journal, 2014, 16, 629-30.	0.1	4
53	The many faces of B regulatory cells. Israel Medical Association Journal, 2014, 16, 631-3.	0.1	13
54	Toll-like receptor-4 expression in infants with pertussis infection. Infection, 2013, 41, 195-198.	4.7	0

#	ARTICLE	IF	CITATIONS
55	Bâ€regulatory cells in autoimmunity and immune mediated inflammation. FEBS Letters, 2013, 587, 2074-2078.	2.8	82
56	Wilmsâ€™ Tumor Gene 1. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 177-180.	1.2	4
57	The expression of lysylâ€oxidase gene family members in myeloproliferative neoplasms. American Journal of Hematology, 2013, 88, 355-358.	4.1	57
58	A5.28â€...Semaphorin3A is a Potent B Cell Regulatory Molecule in SLE. Annals of the Rheumatic Diseases, 2013, 72, A40.3-A41.	0.9	0
59	Semaphorin 3A â€“ a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus. Lupus, 2012, 21, 1266-1270.	1.6	25
60	Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus. Arthritis Research and Therapy, 2012, 14, R146.	3.5	60
61	The Eighth International Congress on Autoimmunity. Israel Medical Association Journal, 2012, 14, 459-64.	0.1	0
62	The involvement of immune semaphorins and neuropilin-1 in lupus nephritis. Lupus, 2011, 20, 1466-1473.	1.6	31
63	Neuropilins and semaphorins â€” from angiogenesis to autoimmunity. Autoimmunity Reviews, 2010, 9, 825-829.	5.8	46
64	Frontier issues in autoimmunity: publications in 2009-2010. Israel Medical Association Journal, 2010, 12, 757-61.	0.1	0
65	New Biological Treatment Options in CSU. , 0, , .		1